CA2097825A1 - Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity - Google Patents

Info

Publication number

CA2097825A1

CA2097825A1 CA002097825A CA2097825A CA2097825A1 CA 2097825 A1 CA2097825 A1 CA 2097825A1 CA 002097825 A CA002097825 A CA 002097825A CA 2097825 A CA2097825 A CA 2097825A CA 2097825 A1 CA2097825 A1 CA 2097825A1

Authority

CA

Canada

Prior art keywords

complement

group

compounds

composition

activity

Prior art date

1990-12-06

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 185
• 239000000203 mixture Substances 0.000 title claims abstract description 143
• 230000000295 complement effect Effects 0.000 title claims abstract description 110
• 102000006834 complement receptors Human genes 0.000 title abstract description 24
• 108010047295 complement receptors Proteins 0.000 title abstract description 23
• 230000002195 synergetic effect Effects 0.000 title abstract description 14
• 230000005965 immune activity Effects 0.000 title description 7
• 150000002894 organic compounds Chemical class 0.000 claims abstract description 50
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
• 230000024203 complement activation Effects 0.000 claims abstract description 31
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 30
• 239000012634 fragment Substances 0.000 claims abstract description 20
• 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 18
• 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
• XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1h-naphthalene-8,2'-3h-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 claims abstract description 14
• 208000026278 immune system disease Diseases 0.000 claims abstract description 7
• 239000003080 antimitotic agent Substances 0.000 claims abstract description 6
• 230000000340 anti-metabolite Effects 0.000 claims abstract description 5
• 229940100197 antimetabolite Drugs 0.000 claims abstract description 5
• 239000002256 antimetabolite Substances 0.000 claims abstract description 5
• 230000000694 effects Effects 0.000 claims description 65
• 230000005764 inhibitory process Effects 0.000 claims description 64
• 206010018910 Haemolysis Diseases 0.000 claims description 38
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
• 230000008588 hemolysis Effects 0.000 claims description 36
• 230000001404 mediated effect Effects 0.000 claims description 28
• -1 CR3 Proteins 0.000 claims description 26
• 210000003743 erythrocyte Anatomy 0.000 claims description 22
• 238000011282 treatment Methods 0.000 claims description 22
• 102100030886 Complement receptor type 1 Human genes 0.000 claims description 13
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 13
• GASOCDUVJSYZGK-UHFFFAOYSA-N spirobenzofuran Chemical compound C1=2C=C(O)C(C)=CC=2OC(O)C21CC(=O)CC2(C)C GASOCDUVJSYZGK-UHFFFAOYSA-N 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 125000000217 alkyl group Chemical group 0.000 claims description 11
• 230000015572 biosynthetic process Effects 0.000 claims description 10
• 125000004432 carbon atom Chemical group C* 0.000 claims description 10
• 150000003839 salts Chemical class 0.000 claims description 10
• 230000009089 cytolysis Effects 0.000 claims description 9
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
• 239000002253 acid Substances 0.000 claims description 6
• 239000003527 fibrinolytic agent Substances 0.000 claims description 6
• 230000005714 functional activity Effects 0.000 claims description 6
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
• 238000001727 in vivo Methods 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 229960000103 thrombolytic agent Drugs 0.000 claims description 6
• 108010067641 Complement C3-C5 Convertases Proteins 0.000 claims description 5
• 102000016574 Complement C3-C5 Convertases Human genes 0.000 claims description 5
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 5
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 5
• 125000003118 aryl group Chemical group 0.000 claims description 5
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
• 102000005962 receptors Human genes 0.000 claims description 5
• 108020003175 receptors Proteins 0.000 claims description 5
• 229960000187 tissue plasminogen activator Drugs 0.000 claims description 5
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 5
• 102000016550 Complement Factor H Human genes 0.000 claims description 4
• 108010053085 Complement Factor H Proteins 0.000 claims description 4
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
• 229960005356 urokinase Drugs 0.000 claims description 4
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
• 108010023197 Streptokinase Proteins 0.000 claims description 3
• 125000001931 aliphatic group Chemical group 0.000 claims description 3
• 125000001118 alkylidene group Chemical group 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
• 229960005202 streptokinase Drugs 0.000 claims description 3
• 150000002148 esters Chemical class 0.000 claims description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
• 125000002252 acyl group Chemical group 0.000 claims 4
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
• 230000002927 anti-mitotic effect Effects 0.000 claims 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
• 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
• 229940041033 macrolides Drugs 0.000 claims 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
• 125000002843 carboxylic acid group Chemical group 0.000 claims 1
• 125000005843 halogen group Chemical group 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• 150000002596 lactones Chemical class 0.000 claims 1
• 230000006870 function Effects 0.000 abstract description 21
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract description 20
• 108010036949 Cyclosporine Proteins 0.000 abstract description 19
• 229960001265 ciclosporin Drugs 0.000 abstract description 14
• 229930182912 cyclosporin Natural products 0.000 abstract description 13
• 230000001225 therapeutic effect Effects 0.000 abstract description 11
• 239000000543 intermediate Substances 0.000 abstract description 8
• 150000003431 steroids Chemical class 0.000 abstract description 5
• 208000027866 inflammatory disease Diseases 0.000 abstract description 4
• 238000002560 therapeutic procedure Methods 0.000 abstract description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
• 239000011885 synergistic combination Substances 0.000 abstract 1
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 69
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
• 239000000243 solution Substances 0.000 description 46
• 238000005481 NMR spectroscopy Methods 0.000 description 43
• 210000004027 cell Anatomy 0.000 description 39
• 238000000034 method Methods 0.000 description 39
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
• 102100031506 Complement C5 Human genes 0.000 description 34
• 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 34
• 102100022133 Complement C3 Human genes 0.000 description 30
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
• 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 29
• 101150107440 crl gene Proteins 0.000 description 29
• 102100032768 Complement receptor type 2 Human genes 0.000 description 28
• 238000002360 preparation method Methods 0.000 description 23
• 235000018102 proteins Nutrition 0.000 description 21
• 238000004809 thin layer chromatography Methods 0.000 description 21
• 230000004913 activation Effects 0.000 description 20
• 238000001994 activation Methods 0.000 description 20
• 201000010099 disease Diseases 0.000 description 18
• 235000019439 ethyl acetate Nutrition 0.000 description 18
• 206010061218 Inflammation Diseases 0.000 description 16
• 230000004154 complement system Effects 0.000 description 16
• 208000035475 disorder Diseases 0.000 description 16
• 230000004054 inflammatory process Effects 0.000 description 16
• 108090000765 processed proteins & peptides Proteins 0.000 description 15
• 208000030507 AIDS Diseases 0.000 description 13
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• 210000000440 neutrophil Anatomy 0.000 description 13
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
• 229910001868 water Inorganic materials 0.000 description 13
• 238000002835 absorbance Methods 0.000 description 12
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 11
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 11
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
• 230000000996 additive effect Effects 0.000 description 10
• 235000001014 amino acid Nutrition 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 210000000265 leukocyte Anatomy 0.000 description 10
• 230000004048 modification Effects 0.000 description 10
• 238000012986 modification Methods 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• 229930105110 Cyclosporin A Natural products 0.000 description 9
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 150000001413 amino acids Chemical class 0.000 description 9
• 230000027455 binding Effects 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 208000010125 myocardial infarction Diseases 0.000 description 9
• 230000037361 pathway Effects 0.000 description 9
• 102000004196 processed proteins & peptides Human genes 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 9
• 241001494479 Pecora Species 0.000 description 8
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
• 238000004587 chromatography analysis Methods 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 230000035755 proliferation Effects 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 7
• DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 7
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
• 230000000747 cardiac effect Effects 0.000 description 7
• 229910052739 hydrogen Inorganic materials 0.000 description 7
• 238000003127 radioimmunoassay Methods 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• 108010078015 Complement C3b Proteins 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 206010018364 Glomerulonephritis Diseases 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
• 230000002612 cardiopulmonary effect Effects 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000010410 reperfusion Effects 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 230000001629 suppression Effects 0.000 description 6
• 238000002054 transplantation Methods 0.000 description 6
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 206010003246 arthritis Diseases 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 239000012043 crude product Substances 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
• 235000019341 magnesium sulphate Nutrition 0.000 description 5
• 210000003622 mature neutrocyte Anatomy 0.000 description 5
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 125000001424 substituent group Chemical group 0.000 description 5
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 238000004440 column chromatography Methods 0.000 description 4
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
• 208000037765 diseases and disorders Diseases 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 230000002107 myocardial effect Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 125000003003 spiro group Chemical group 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical class C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 3
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 206010011951 Decompression Sickness Diseases 0.000 description 3
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 206010057249 Phagocytosis Diseases 0.000 description 3
• 241000219061 Rheum Species 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000000172 allergic effect Effects 0.000 description 3
• 239000003146 anticoagulant agent Substances 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 239000007795 chemical reaction product Substances 0.000 description 3
• 230000035605 chemotaxis Effects 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000008021 deposition Effects 0.000 description 3
• 230000001627 detrimental effect Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 238000000921 elemental analysis Methods 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 238000001631 haemodialysis Methods 0.000 description 3
• 230000000322 hemodialysis Effects 0.000 description 3
• 230000002949 hemolytic effect Effects 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 3
• 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
• 230000009871 nonspecific binding Effects 0.000 description 3
• 150000002977 perillyl alcohol derivatives Chemical class 0.000 description 3
• 230000008782 phagocytosis Effects 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 235000015320 potassium carbonate Nutrition 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 238000007363 ring formation reaction Methods 0.000 description 3
• 230000035939 shock Effects 0.000 description 3
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
• 159000000000 sodium salts Chemical class 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 150000003536 tetrazoles Chemical group 0.000 description 3
• 230000002537 thrombolytic effect Effects 0.000 description 3
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
• ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
• 101150041968 CDC13 gene Proteins 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• 101710091342 Chemotactic peptide Proteins 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 108010028780 Complement C3 Proteins 0.000 description 2
• 102000016918 Complement C3 Human genes 0.000 description 2
• 101710143772 Complement receptor type 2 Proteins 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 206010013700 Drug hypersensitivity Diseases 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 108010071289 Factor XIII Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 206010020850 Hyperthyroidism Diseases 0.000 description 2
• 208000024781 Immune Complex disease Diseases 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 108010047620 Phytohemagglutinins Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 101100006979 Rattus norvegicus C4 gene Proteins 0.000 description 2
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 101710120037 Toxin CcdB Proteins 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 125000003158 alcohol group Chemical group 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000002587 anti-hemolytic effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 150000003937 benzamidines Chemical class 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 229920001429 chelating resin Polymers 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000005482 chemotactic factor Substances 0.000 description 2
• WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 229940000425 combination drug Drugs 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 108010052926 complement C3d,g Proteins 0.000 description 2
• 239000004074 complement inhibitor Substances 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
• 230000008034 disappearance Effects 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003814 drug Substances 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 229940012444 factor xiii Drugs 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 208000007475 hemolytic anemia Diseases 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 150000003949 imides Chemical class 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 125000000468 ketone group Chemical group 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 238000011694 lewis rat Methods 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• RNVFYQUEEMZKLR-UHFFFAOYSA-N methyl 3,5-dihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=CC(O)=C1 RNVFYQUEEMZKLR-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 230000001885 phytohemagglutinin Effects 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 235000011181 potassium carbonates Nutrition 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 208000005333 pulmonary edema Diseases 0.000 description 2
• LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000019254 respiratory burst Effects 0.000 description 2
• 201000004193 respiratory failure Diseases 0.000 description 2
• IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 229910001961 silver nitrate Inorganic materials 0.000 description 2
• NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• 208000005057 thyrotoxicosis Diseases 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• YFOOEYJGMMJJLS-UHFFFAOYSA-N 1,8-diaminonaphthalene Chemical class C1=CC(N)=C2C(N)=CC=CC2=C1 YFOOEYJGMMJJLS-UHFFFAOYSA-N 0.000 description 1
• YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
• DCYAOXOBKROXKE-UHFFFAOYSA-N 1-carbamimidoylpiperidine-4-carboxylic acid Chemical class NC(=N)N1CCC(C(O)=O)CC1 DCYAOXOBKROXKE-UHFFFAOYSA-N 0.000 description 1
• APNUEDCZMXPTFS-UHFFFAOYSA-N 1-methoxy-3-(methoxymethoxy)benzene Chemical compound COCOC1=CC=CC(OC)=C1 APNUEDCZMXPTFS-UHFFFAOYSA-N 0.000 description 1
• UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
• WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
• VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• WMXCDAVJEZZYLT-UHFFFAOYSA-M 2-methylpropane-2-thiolate Chemical compound CC(C)(C)[S-] WMXCDAVJEZZYLT-UHFFFAOYSA-M 0.000 description 1
• 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 1
• ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 2-phenyl-1h-imidazole Chemical compound C1=CNC(C=2C=CC=CC=2)=N1 ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• ZRQPOQRDNYJQNB-UHFFFAOYSA-N 4,5,6-trimethyl-1h-pyrimidin-2-one Chemical class CC1=NC(=O)NC(C)=C1C ZRQPOQRDNYJQNB-UHFFFAOYSA-N 0.000 description 1
• HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
• ZEYHEAKUIGZSGI-UHFFFAOYSA-M 4-methoxybenzoate Chemical compound COC1=CC=C(C([O-])=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-M 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
• 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
• 108010089414 Anaphylatoxins Proteins 0.000 description 1
• 241000156948 Aphantopus hyperantus Species 0.000 description 1
• 208000000104 Arthus reaction Diseases 0.000 description 1
• 208000004300 Atrophic Gastritis Diseases 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 206010061688 Barotrauma Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 241001598984 Bromius obscurus Species 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 208000007596 Byssinosis Diseases 0.000 description 1
• 101150071803 CR2 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 239000005973 Carvone Substances 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 241000511343 Chondrostoma nasus Species 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 1
• 101710172562 Cobra venom factor Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108010028778 Complement C4 Proteins 0.000 description 1
• 108010077762 Complement C4b Proteins 0.000 description 1
• 108010028773 Complement C5 Proteins 0.000 description 1
• 108090000044 Complement Factor I Proteins 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 108090000056 Complement factor B Proteins 0.000 description 1
• 102000003712 Complement factor B Human genes 0.000 description 1
• 102100034622 Complement factor B Human genes 0.000 description 1
• 102100035431 Complement factor I Human genes 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010060902 Diffuse alveolar damage Diseases 0.000 description 1
• IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 208000036495 Gastritis atrophic Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000000913 Kidney Calculi Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 206010024227 Lepromatous leprosy Diseases 0.000 description 1
• 229910010082 LiAlH Inorganic materials 0.000 description 1
• 229910010084 LiAlH4 Inorganic materials 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 240000005265 Lupinus mutabilis Species 0.000 description 1
• 235000008755 Lupinus mutabilis Nutrition 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000948268 Meda Species 0.000 description 1
• 241001068914 Melicope knudsenii Species 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101100333728 Mus musculus Ercc8 gene Proteins 0.000 description 1
• 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
• 229910017974 NH40H Inorganic materials 0.000 description 1
• DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 241000364057 Peoria Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038422 Renal cortical necrosis Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 206010051447 Retinopathy haemorrhagic Diseases 0.000 description 1
• 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
• 235000019095 Sechium edule Nutrition 0.000 description 1
• 208000036366 Sensation of pressure Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 241001279361 Stachybotrys Species 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010047112 Vasculitides Diseases 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 125000000746 allylic group Chemical group 0.000 description 1
• 125000000320 amidine group Chemical group 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000003266 anti-allergic effect Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000001518 anti-nephritic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000010002 chemokinesis Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 210000003792 cranial nerve Anatomy 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 150000001923 cyclic compounds Chemical class 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 150000001934 cyclohexanes Chemical class 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
• 229940008406 diethyl sulfate Drugs 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000007646 directional migration Effects 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• CVRSZZJUWRLRDE-PWNZVWSESA-N drimane Chemical compound CC1(C)CCC[C@]2(C)[C@@H](C)[C@@H](C)CC[C@H]21 CVRSZZJUWRLRDE-PWNZVWSESA-N 0.000 description 1
• 229930001542 drimane Natural products 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 150000002170 ethers Chemical group 0.000 description 1
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000001156 gastric mucosa Anatomy 0.000 description 1
• 210000001282 glomerular podocyte Anatomy 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930182478 glucoside Natural products 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
• 229960002867 griseofulvin Drugs 0.000 description 1
• 230000036433 growing body Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 150000004820 halides Chemical group 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 108010057863 heparin receptor Proteins 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 238000006897 homolysis reaction Methods 0.000 description 1
• 230000000652 homosexual effect Effects 0.000 description 1
• 125000005597 hydrazone group Chemical group 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000005462 imide group Chemical group 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000002541 isothioureas Chemical class 0.000 description 1
• 208000005430 kidney cortex necrosis Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
• GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
• YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000006138 lithiation reaction Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
• 239000003055 low molecular weight heparin Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 125000006606 n-butoxy group Chemical group 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940090008 naprosyn Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 230000003589 nefrotoxic effect Effects 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 231100000381 nephrotoxic Toxicity 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 238000002640 oxygen therapy Methods 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 125000002075 perillyl alcohol group Chemical group 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000008196 pharmacological composition Substances 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 239000000700 radioactive tracer Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 239000012508 resin bead Substances 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 125000005920 sec-butoxy group Chemical group 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 231100000004 severe toxicity Toxicity 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229910001923 silver oxide Inorganic materials 0.000 description 1
• 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002356 skeleton Anatomy 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 125000000565 sulfonamide group Chemical group 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical class FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• QGVNJRROSLYGKF-UHFFFAOYSA-N thiobarbital Chemical compound CCC1(CC)C(=O)NC(=S)NC1=O QGVNJRROSLYGKF-UHFFFAOYSA-N 0.000 description 1
• 150000005075 thioxanthenes Chemical class 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000005039 triarylmethyl group Chemical group 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1